ARTICLE | Company News
V.I. Technologies, Haemonetics Corp. deal
January 31, 2000 8:00 AM UTC
The companies will develop a commercial-scale system to remove VITX's Inactine, which uses small molecule electrophilic nucleic acid binders to inactivate viruses, from treated red blood cell concentr...